|
Malignant Head and Neck Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Similarly, tobacco-betel quid chewers carrying CYP1A1 TC/CC + GSTM1 null genotypes also had several fold increased risk of HNC (P < 0.001).
|
25724184 |
2015 |
|
Malignant Head and Neck Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The CYP1A1 CC genotype was significantly associated with HNC risk (P=0.045).
|
26514474 |
2015 |
|
Malignant Head and Neck Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms in CYP1A1 and CYP2D6 may significantly associate with HNC in the Tunisian population.
|
24449363 |
2014 |
|
Malignant Head and Neck Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Data for immunohistochemistry showed that CYP1A1 and GSTT1 was down expressed whereas GSTP1 was over expressed in HNC tissues compared with adjacent normal control tissues.
|
22918668 |
2013 |
|
Malignant Head and Neck Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multifactor dimensionality reduction approach showed that the three-factor model, including smoking status, CYP1A1 T3801C, and GSTM1 copy number variants, conferred more than fourfold increased risk of head and neck cancer (odds ratio 4.89; 95% confidence interval: 3.15-7.32, p < 0.01).
|
21438663 |
2011 |
|
Malignant Head and Neck Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results revealed that CYP1A1, GSTM1 and GSTT1 are downregulated in the head and neck cancer progression while GSTP1 is upregulated.
|
21545198 |
2011 |
|
Malignant Head and Neck Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Those individuals carrying at least one CYP1A1 m1 or m2 variant allele were at a 2-fold elevated risk for head and neck cancer.
|
20887941 |
2010 |
|
Malignant Head and Neck Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
GSTM1 copy number variations and CYP1A1 polymorphisms individually as well in interaction with tobacco consumption may increase the risk of HNC.
|
20491576 |
2010 |
|
Malignant Head and Neck Neoplasm
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
We also observed significant interaction between smoking and methylation status of CYP1A1 (P 0.029) and CYP2A13 (P -0.034) in head and neck cancer.
|
20846153 |
2010 |
|
Malignant Head and Neck Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
GSTM1, GSTT1, GSTP1, XRCC1 codons 194 and 399, and CYP1A1 codon 462 were examined by meta-analyses, and significant relations were found between the GSTM1-null genotype and an increased risk for HNC.
|
18425322 |
2008 |
|
Malignant Head and Neck Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings corroborate metabolic genes interactions, especially for CYP1A1 462Val alleles and GSTM1 homozygous deletion, in the development of head and neck cancer in the investigated population groups in Poland.
|
18590468 |
2008 |
|
Malignant Head and Neck Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
GSTM1 null alone or associated with CYP1A1 increased the risk of head and neck cancer; the CYP2E1PstI mutated allele increased the risk for only oral cancer.
|
16721740 |
2006 |
|
Malignant Head and Neck Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the meta-analysis, the summary odds ratios (ORs) for head and neck cancer were 1.23 [95% confidence interval (95% CI), 1.06-1.42] for the GSTM1 null genotype, 1.17 (95% CI, 0.98-1.40) for the GSTT1 null genotype, 1.10 (95% CI, 0.92-1.31) for carrying the GSTP1 Val105 allele, and 1.35 (95% CI, 0.95-1.82) for carrying the CYP1A1 Val462 allele.
|
14693745 |
2003 |
|
Malignant Head and Neck Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, with a logistic regression model to control for known risk factors, we were unable to demonstrate a significant association with head and neck cancer for any of the polymorphisms tested, including CYP1A1.
|
10941163 |
2000 |
|
Malignant Head and Neck Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
The occurrence of polymorphic variants in the GSTM1, GSTT1, and CYP1A1 genes did not differ between the groups investigated, therefore indicating no significant contribution to the development of head and neck cancer.
|
9486585 |
1998 |